Rein Therapeutics completed a $57.5 million underwritten public offering, including full exercise of the over-allotment option, selling 57.5 million shares at $1.00 each. The proceeds will fully fund the company's ongoing Phase 2 clinical trial of LTI-03 for idiopathic pulmonary fibrosis (IPF) and support operations through 2028. The offering attracted both new and existing healthcare-focused investors, strengthening Rein's financial position to advance its clinical and operational goals. The company expects the funds to cover clinical development, manufacturing, regulatory activities, and general corporate purposes.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
